DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Derek Archila - 1 Wells - 1 Michael - 1 Matt Akers - 1 Akers - 1 Wells Fargo - 1 — CNBC's Michael Bloom - 1
Top related locs:
Wells Fargo 3Q23
Top related orgs:
Nasdaq - 1 Wells - 1 Microsoft - 1 Aerospace - 1 L3Harris Technologies - 1 Caesars Entertainment - 1

Search resuls for: "Derek Archila"


4 mentions found


☆ Wells Fargo’s top fourth-quarter trade ideas include a biopharma stock that could rally 60% off a new treatment
  + stars: | 2023-10-06 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +2 min
As investors approach year-end, Wells Fargo is offering its top high-conviction and catalyst-driven trade ideas for the fourth quarter of 2023. Question marks notwithstanding, analysts at Wells Fargo recently shared their top 10 tactical ideas for the next three months. But the worst could now be over, wrote analyst Derek Archila. APLS YTD mountain APLS YTD chart Within technology, Wells Fargo highlighted Microsoft as a top pick. Wells Fargo also included hotel and casino company Caesars Entertainment and discount retailer Ollie's Bargain Outlet among its top trade ideas for the fourth quarter.
Persons: Derek Archila, Wells, Michael, Matt Akers, Akers, Wells Fargo, — CNBC's Michael Bloom Organizations: Nasdaq, Wells, Microsoft, Aerospace, L3Harris Technologies, Caesars Entertainment Locations: Wells Fargo, 3Q23
☆ Wells Fargo says this little-known biotech company could rally more than 80%
  + stars: | 2023-04-17 | by ( Hakyung Kim | Https | Www.Linkedin.Com In Hakyungkim | ) www.cnbc.com   time to read: +1 min
Viridian Therapeutics is "a sight for sore eyes," according to Wells Fargo. Viridian's thyroid eye disease treatment VRDN-001 is currently undergoing clinical testing. Wells Fargo is confident it will gain market share even with Horizon's Tepezza already established in the market. Results for VRDN-001's phase one and two trials in chronic thyroid eye disease are expected in the second half of 2023. VRDN 1Y mountain Viridian Therapeutics stock —CNBC's Michael Bloom contributed to this report.
☆ Wells Fargo says this biopharmaceutical stock could double due to drug catalysts
  + stars: | 2023-03-21 | by ( Alex Harring | ) www.cnbc.com   time to read: +1 min
Catalysts coming for Ventyx 's immunology and inflammation projects could help the stock more than double its share value, Wells Fargo said. Analyst Derek Archila initiated coverage of the biopharmaceutical stock at overweight and set a target price for the stock at $77. His price target implies the stock will surge 103.4% over the next year from where it closed Monday. But Archila said there's a likely chance that the company could set a new bar with its trial for moderately to severely active ulcerative colitis. Wall Street expectations for the read-out coming in the second half of this year would be "highly impressive" if met, Archila said.
☆ This under-the-radar biotech stock can surge 40% on upcoming cancer treatment data, Wells Fargo says
  + stars: | 2023-03-09 | by ( Sarah Min | ) www.cnbc.com   time to read: +1 min
It's time to buy Exelixis shares ahead of readouts on the biotech firm's cancer treatment, according to Wells Fargo. Analyst Derek Archila initiated coverage of Exelixis with an overweight rating, saying the biotech company's consistent revenue growth and upcoming clarity around the firm's cancer product called cabozantinib will drive upside. "We like cabo's near-term growth prospects and believe upcoming clarity on its [loss of exclusivity] will serve as a catalyst for shares. Exelixis shares are 2% higher this year, after falling 12% in 2022. EXEL 1D mountain Exelixis shares 1-day —CNBC's Michael Bloom contributed to this report.
0 next >>
Total: 4